Mar 2, 2021 Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure and Mortality in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS
Feb 2, 2021 Cerecor Announces Fast Track Designation for CERC-803 for the Treatment of Leukocyte Adhesion Deficiency Type II
Jan 20, 2021 Cerecor Announces Proceeds from Option to Purchase Additional Shares of Common Stock Bringing Public Offering Proceeds to $40.7 Million
Jan 12, 2021 Cerecor Inc. Announces Closing of $36.4 Million Public Offering of Common Stock and Pre-Funded Warrants
Jan 7, 2021 Cerecor Inc. Announces Pricing of $36.4 Million Public Offering of Common Stock and Pre-Funded Warrants
Jan 5, 2021 Cerecor Announces Successful Proof of Concept Data for CERC-002, a Unique LIGHT-Neutralizing Antibody, in Patients Hospitalized with COVID-19 ARDS
Dec 22, 2020 Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for the Treatment of Still’s Disease
Dec 16, 2020 Cerecor Announces First Patient Dosed in a Phase 1b Clinical Trial of CERC-007 for the Treatment of Relapsed or Refractory Multiple Myeloma
